Canagliflozin (invokana), a novel oral agent for type-2 diabetes.

Article Details

Citation

Copy to clipboard

Sarnoski-Brocavich S, Hilas O

Canagliflozin (invokana), a novel oral agent for type-2 diabetes.

P T. 2013 Nov;38(11):656-66.

PubMed ID

24391386 [ View in PubMed

]

Abstract

Not Available

DrugBank Data that Cites this Article

Drug Enzymes

Drug	Enzyme	Kind	Organism	Pharmacological Action	Actions
Canagliflozin	UDP-glucuronosyltransferase 1-9	Protein	Humans	Unknown	Substrate	Details
Canagliflozin	UDP-glucuronosyltransferase 2B4	Protein	Humans	Unknown	Substrate	Details

Drug Interactions

• Approved
• Vet approved
• Nutraceutical
• Illicit
• Withdrawn
• Investigational
• Experimental
• All Drugs

Drugs	Interaction
Integrate drug-drug interactions in your software
Canagliflozin Phenytoin	The serum concentration of Canagliflozin can be decreased when it is combined with Phenytoin.
Canagliflozin Fosphenytoin	The serum concentration of Canagliflozin can be decreased when it is combined with Fosphenytoin.